An Expanded Access IND to Evaluate the Safety and Efficacy of Autologous HBadMSCs for the Treatment of a Single Pediatric Patient With Congenital Muscular Dystrophy.
Latest Information Update: 04 Aug 2022
At a glance
- Drugs Autologous adipose derived mesenchymal stem cells Hope Biosciences (Primary)
- Indications Muscular dystrophies; Psoriatic arthritis; Spinal cord injuries
- Focus Expanded access; Therapeutic Use
- Sponsors Hope Biosciences
- 16 Dec 2021 New trial record